Dermata Therapeutics, Inc.
DRMA
$6.45
$0.2183.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.77M | 4.31M | 4.39M | 4.47M | 4.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.65M | 12.51M | 11.53M | 10.12M | 8.97M |
| Operating Income | -11.65M | -12.51M | -11.53M | -10.12M | -8.97M |
| Income Before Tax | -11.46M | -12.29M | -11.27M | -9.82M | -8.69M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.46 | -12.29 | -11.27 | -9.82 | -8.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.46M | -12.29M | -11.27M | -9.82M | -8.69M |
| EBIT | -11.65M | -12.51M | -11.53M | -10.12M | -8.97M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -75.86 | -141.99 | -199.59 | -260.07 | -312.60 |
| Normalized Basic EPS | -47.41 | -88.74 | -124.74 | -162.54 | -195.38 |
| EPS Diluted | -75.86 | -141.99 | -199.59 | -260.07 | -312.60 |
| Normalized Diluted EPS | -47.41 | -88.74 | -124.74 | -162.54 | -195.38 |
| Average Basic Shares Outstanding | 1.08M | 611.30K | 299.60K | 165.40K | 115.70K |
| Average Diluted Shares Outstanding | 1.08M | 611.30K | 299.60K | 165.40K | 115.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |